Lilly Playing Catch Up In Oncology
The big pharma is chasing the competition in multiple areas of oncology, bringing forward offerings in CDK 4/6, as well as PD-L1.
You may also be interested in...
The two big pharmas are working together in oncology in an effort to advance combination therapies in both their growing, but young oncology pipelines.
The ASCO abstracts are out – and with them a scramble to see exactly what will be hitting the headlines in early June. Here, with the help of Sagient's BioMedTracker, Scrip takes a look at some of the more interesting studies due to be presented in Chicago in a couple weeks.
Data to be presented at the American Society of Oncology meeting in June on cyclin-dependent kinase 4/6 inhibitors, an important new category of drugs to treat breast cancer, suggest Pfizer Inc. is well positioned to maintain its lead in the category even as new competition prepares to enter the market.